AbbVie’s ABBV-466 Achieves 40.5% Endoscopic Remission in Crohn’s Trial

AbbVie's Phase 2a TARGET-CD data for ABBV-466 signal a meaningful shift in biologic complexity for CMOs and fill-finish operations: a dual-targeting molecule combining anti-IL-23 p19 (risankizumab) and anti-α4β7 (trosunilimab) activity is advancing through the pipeline with endoscopic remission rates that outperform either component in monotherapy, raising the manufacturing and regulatory bar for next-generation IBD biologics.

In the open-label, treat-through Phase 2a study, 30.2% of ABBV-466-treated patients achieved endoscopic remission at Week 12, the primary endpoint, versus 21.3% on anti-IL-23 p19 monotherapy and 18.0% on anti-α4β7 monotherapy. By Week 24, the ABBV-466 arm reached 40.5% endoscopic remission compared with 22.4% and 20.0% in the risankizumab and trosunilimab arms, respectively. The widening treatment difference over time is a notable efficacy signal in a population where 75% had failed at least one advanced therapy.

Gene expression analyses added a mechanistic layer: ABBV-466-treated patients showed colonic epithelial repair and barrier restoration by Week 12, followed by tissue remodeling and metabolic changes at Week 24, findings not generally observed with either monotherapy. The 300-patient study enrolled across the full spectrum of disease severity, including 9.3% who had failed prior IL-23 therapy and 12% who had failed a JAK inhibitor, reflecting a heavily pre-treated population that mirrors real-world referral patterns.

For biologics manufacturers and contract development and manufacturing organizations, the dual-targeting architecture of ABBV-466 introduces process development considerations that differ materially from single-agent monoclonal antibodies. Characterization requirements, formulation stability across two active moieties, and the fill-finish precision demanded by combination biologics will require early alignment between AbbVie's technical teams and any external manufacturing partners. Regulatory submissions under 21 CFR Part 211 and ICH Q10 quality system expectations will need to account for the added analytical complexity of a bispecific or co-formulated construct as the program moves toward later-phase development.

The TARGET-CD findings were presented as a late-breaking abstract at the 2026 United European Gastroenterology Week (UEGW) Congress in Barcelona, October 17–20, with AbbVie citing the data as central to its strategy of building the next generation of its IBD portfolio around the complex biology of Crohn's disease.

The transition from Phase 2a to a potential Phase 3 program will be the next measurable checkpoint for manufacturing readiness and process validation planning across AbbVie's biologics network.

Source: AbbVie News Center via PR Newswire, 19 October 2026.